Remote Ischemic Preconditioning With Postconditioning in Heart Transplantation Surgery
Not Applicable
Completed
- Conditions
- End Stage Heart DiseaseHeart FailureMyocardial Ischemic Reperfusion InjuryCardiomyopathy
- Registration Number
- NCT02149316
- Lead Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Brief Summary
The purpose of this study is to determine whether remote ischemic preconditioning with postconditioning (RIPC+RIPostC) reduces myocardial injury and improves clinical outcomes in heart transplantation surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- scheduled for elective orthotopic heart transplantation surgery
Exclusion Criteria
- peripheral vascular disease affecting the upper arms
- mechanical circulatory support before surgery
- taking the antidiabetic sulphonylurea, glibenclamide
- cold ischemic time of donor heart > 12 hours
- repeated heart surgery
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method serum cardiac troponin I (cTnI) within 72 hours after aortic declamping
- Secondary Outcome Measures
Name Time Method plasma microRNA-133b (miR-133b) within 72 hours after aortic declamping plasma microRNA-208a (miR-208a) within 72 hours after aortic declamping
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie RIPC+RIPostC's cardioprotective effects in heart transplantation?
How does RIPC+RIPostC compare to standard ischemic preconditioning in reducing donor heart injury?
Which biomarkers are associated with myocardial ischemic reperfusion injury in heart transplant recipients?
What are the potential adverse events of RIPC+RIPostC in heart transplantation and how are they managed?
Are there combination therapies with RIPC+RIPostC that enhance cardioprotection in heart failure patients?
Trial Locations
- Locations (1)
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, CAMS and PUMC
🇨🇳Beijing, China
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, CAMS and PUMC🇨🇳Beijing, China